U.S. Naltrexone And Buprenorphine Market Size & Outlook

The naltrexone and buprenorphine market in the United States is expected to reach a projected revenue of US$ 3,464.0 million by 2033. A compound annual growth rate of 9.3% is expected of the United States naltrexone and buprenorphine market from 2025 to 2033.
Revenue, 2024 (US$M)
$1,469.7
Forecast, 2033 (US$M)
$3,464.0
CAGR, 2025 - 2033
9.3%
Report Coverage
U.S.

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

U.S. naltrexone and buprenorphine market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

U.S. naltrexone and buprenorphine market highlights

  • The U.S. naltrexone and buprenorphine market generated a revenue of USD 1,469.7 million in 2024 and is expected to reach USD 3,464.0 million by 2033.
  • The U.S. market is expected to grow at a CAGR of 9.3% from 2025 to 2033.
  • In terms of segment, naltrexone was the largest revenue generating product in 2024.
  • Naltrexone is the most lucrative product segment registering the fastest growth during the forecast period.


Naltrexone and buprenorphine market data book summary

Market revenue in 2024USD 1,469.7 million
Market revenue in 2033USD 3,464.0 million
Growth rate9.3% (CAGR from 2025 to 2033)
Largest segmentNaltrexone
Fastest growing segmentNaltrexone
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationBuprenorphine, Naltrexone
Key market players worldwideIndivior PLC Ordinary Share, Collegium Pharmaceutical Inc, Alkermes PLC, Orexo AB, Titan Pharmaceuticals Inc, Omeros Corp, Camurus AB, Sun Pharmaceutical Industries


Other key industry trends

  • In terms of revenue, U.S. accounted for 35.2% of the global naltrexone and buprenorphine market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In North America, U.S. naltrexone and buprenorphine market is projected to lead the regional market in terms of revenue in 2033.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 3,464.0 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Naltrexone and Buprenorphine Market Companies

Name Profile # Employees HQ Website
Omeros Corp View profile 198 201 Elliott Avenue West, Seattle, WA, United States, 98119 https://www.omeros.com
Camurus AB View profile 218 Ideon Science Park, Lund, Sweden, SE-223 70 https://www.camurus.com
Orexo AB View profile 113 Virdings alle 32 A, P.O. Box 303, Uppsala, Sweden, 75105 https://www.orexo.com
Titan Pharmaceuticals Inc View profile 4 400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, United States, 94080 https://www.titanpharm.com
Alkermes PLC View profile 2100 1 Burlington Road, Connaught House, Dublin, Ireland, D04 C5Y6 https://www.alkermes.com
Indivior PLC Ordinary Share View profile 1164 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, United States, 23235 https://www.indivior.com
Collegium Pharmaceutical Inc View profile 197 100 Technology Center Drive, Stoughton, MA, United States, 02072 https://www.collegiumpharma.com
Sun Pharmaceutical Industries View profile 10001+ Mumbai, Maharashtra, India, Asia http://www.sunpharma.com

U.S. naltrexone and buprenorphine market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to naltrexone and buprenorphine market will help companies and investors design strategic landscapes.


Naltrexone was the largest segment with a revenue share of 88.14% in 2024. Horizon Databook has segmented the U.S. naltrexone and buprenorphine market based on buprenorphine, naltrexone covering the revenue growth of each sub-segment from 2021 to 2033.


Reasons to subscribe to U.S. naltrexone and buprenorphine market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. naltrexone and buprenorphine market databook

  • Our clientele includes a mix of naltrexone and buprenorphine market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. naltrexone and buprenorphine market , including forecasts for subscribers. This country databook contains high-level insights into U.S. naltrexone and buprenorphine market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

U.S. naltrexone and buprenorphine market size, by product, 2021-2033 (US$M)

U.S. Naltrexone and Buprenorphine Market Outlook Share, 2024 & 2033 (US$M)

U.S. naltrexone and buprenorphine market size, by product, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online